Related references
Note: Only part of the references are listed.Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease
Pablo A. Urena-Torres et al.
CLINICAL KIDNEY JOURNAL (2019)
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword
David C. Wheeler et al.
KIDNEY INTERNATIONAL SUPPLEMENTS (2017)
Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis
Xiao-Hua Li et al.
NEPHROLOGY (2015)
Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial
Carmine Zoccali et al.
HYPERTENSION (2014)
Effect of Paricalcitol on Left Ventricular Mass and Function in CKD-The OPERA Trial
Angela Yee-Moon Wang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Prevalence and progression of cardiovascular calcifications in peritoneal dialysis patients: A prospective study
Maurizio Gallieni et al.
BONE (2012)
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease The PRIMO Randomized Controlled Trial
Ravi Thadhani et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options
John Cunningham et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
CYP24A1 and kidney disease
Martin Petkovich et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2011)
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
Juergen Floege et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Outcomes Associated with Serum Calcium Level in Men with Non-Dialysis-Dependent Chronic Kidney Disease
Csaba P. Kovesdy et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
Dick de Zeeuw et al.
LANCET (2010)
Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)
Rohit Bhuriya et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial
Steven Fishbane et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Association of Secondary Hyperparathyroidism with CKD Progression, Health Care Costs and Survival in Diabetic Predialysis CKD Patients
Glen T. Schumock et al.
NEPHRON CLINICAL PRACTICE (2009)
Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort
Adeera Levin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)
Francesca Tentori et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease
C. P. Kovesdy et al.
KIDNEY INTERNATIONAL (2008)
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease
A. Levin et al.
KIDNEY INTERNATIONAL (2007)
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD
D Coyne et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Share Paper
